Holen Sie sich die Stockscreener-App
20.39
0.39%
-0.08
Handel nachbörslich:
20.69
0.30
+1.47%
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Bank of America Corp DE Buys New Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics Stock Price Forecast. Should You Buy DNLI? - StockInvest.us
SK Biopharm takes 1st Bio’s LRRK2/c-Abl inhibitor in $315M deal - BioWorld News
Transcript : Denali Therapeutics Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-09-2026 09 - marketscreener.com
DNLI: AVLAYAH's launch validates a brain-targeted biologics platform, driving pipeline and global expansion - TradingView
Denali Therapeutics at Morgan Stanley conference: launch momentum builds By Investing.com - Investing.com Canada
The Technical Signals Behind (DNLI) That Institutions Follow - Stock Traders Daily
Denali at Cantor global healthcare conference: launch gains traction By Investing.com - Investing.com India
Denali Therapeutics (DNLI) Institutional Ownership 2026 $DNLI - MarketBeat
Denali Therapeutics Insider Transactions: Officer Peter Scott Chin to Sell 1,654 Shares, Director Nancy Thornberry Sells 11,439 Shares (NASDAQ: DNLI) - Kalkine Media
Denali Therapeutics director sells $261,928 in stock By Investing.com - Investing.com UK
Denali Therapeutics director sells $261,928 in stock - investing.com
Denali Therapeutics (NASDAQ: DNLI) holder to sell shares to cover tax on stock units - Stock Titan
Denali Therapeutics Director Nancy Thornberry Executes Two Stock Sales Under Rule 10b5-1 Plan - Kalkine Media
Denali Therapeutics Insider Sold Shares Worth $261,929, According to a Recent SEC Filing - marketscreener.com
Director Nancy Thornberry plans Denali (NASDAQ: DNLI) stock sale - Stock Titan
Denali Therapeutics (NASDAQ: DNLI) exec plans 2,768-share Rule 144 sale - stocktitan.net
B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating - finance.yahoo.com
Denali (DNLI) Session: Finishes 2.89% Lower at $24.20; Technical View: Price Remains Between $22.99 Support and $25.41 ResistanceOBV Trend Line - vinanet.vn
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome - Reuters
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript - AOL.com
145,045 Shares in Denali Therapeutics Inc. $DNLI Purchased by Great Lakes Advisors LLC - MarketBeat
Denali’s DNL921 Trial: Early Alzheimer’s Safety Data That Could Shape Long-Term Upside - TipRanks
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? - TradingView
Edmond DE Rothschild Holding S.A. Invests $4.25 Million in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali (DNLI) Financial Update: The Available Earnings Metric Delivers a Miss for This Review; Market Reaction: Shares Finish 3.25% UpDividend Increase Stocks - vinanet.vn
Denali Therapeutics: Bullish On AVLAYAH And Their Prospects (NASDAQ:DNLI) - Seeking Alpha
Bank of America Corp DE Boosts Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report - Sahm
SCS Capital Management LLC Takes Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund - Kalkine Media
Denali Therapeutics Inc.: Fundamental Analysis and Financial Ratings | DNLI | US24823R1059 - marketscreener.com
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock - MarketBeat
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One (NASDAQ:DNLI) - Seeking Alpha
Sei Investments Co. Purchases Shares of 52,235 Denali Therapeutics Inc. $DNLI - MarketBeat
J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Equities Analysts Set Expectations for DNLI Q3 Earnings - MarketBeat
E. Ohman J or Asset Management AB Acquires New Shares in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) holder to sell 2,857 restricted shares via broker - Stock Titan
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June R - GuruFocus
Weekly Recap: Q2 revenue, big net loss and DNL126 Phase 3 with 2027 BLA - TradingView
Denali climbs past Avlayah expectations with $3.6M in revenue - BioSpace
(DNLI) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
The Manufacturers Life Insurance Company Lowers Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42 - Moomoo
Denali Therapeutics (DNLI) Is Up 7.9% After AVLAYAH Launch Drives First Full-Quarter Commercial Revenue - Sahm
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - Yahoo Finance
UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating - marketscreener.com
Denali Therapeutics Inc. Stock 12‑Month Price Target Raised to $35.44, Implies 43% Upside - TradingView
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $41 - Moomoo
Denali Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating - marketscreener.com
Earnings call transcript: Denali Therapeutics posts Q2 2026 revenue miss as AVLAYAH launch builds - Investing.com Nigeria
Denali Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:DNLI) 2026-08-07 - Seeking Alpha
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
DNLI SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Denali Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Denali Therapeutics Q2 Earnings Call Highlights - MarketBeat
Denali Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):